Review Article

Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease

M. S. Mirza

SpR Surgery, Ninewells Hospital, 65 Lister Court, Dundee DD2 1UY, UK

Correspondence should be addressed to M. S. Mirza, msmirza@doctors.org.uk

Received 4 April 2011; Accepted 1 May 2011

Academic Editors: K. D. Mullen, C. T. Shun, and W. Vogel

Copyright © 2011 M. S. Mirza. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of clinicopathologic conditions ranging from steatosis alone to nonalcoholic steatohepatitis (NASH), with varying risks for progression to cirrhosis and hepatocellular carcinoma. There is mounting evidence that NAFLD not only complicates obesity, but also perpetuates its metabolic consequences. Critical event that leads to progressive liver injury in NAFLD is unknown. Obesity reflects a generalized proinflammatory state with its increased inflammatory markers like C reactive protein, IL-6, IL-8, IL-10, PAI-1, TNF-α, and hepatocyte growth factor. The elevated production of these adipokines is increasingly considered to be important in the development of diseases linked to obesity and the metabolic syndrome. Disordered cytokine production is likely to play a role in the pathogenesis of NAFLD. There is no effective treatment for NAFLD, though weight loss may halt disease progression and revert histological changes, the underlying mechanism remaining elusive. All stages of the disease pathway from prevention, early identification/diagnosis, and treatment require an understanding of the pathogenesis of liver injury in NAFLD.

1. Introduction

With the rapidly growing prevalence of obesity [1] throughout the world, morbidity and mortality related to its complications is on the rise [2]. Obesity is considered a gateway disease. Defined and classified by body mass index (Table 1), individuals with severe obesity have a disproportionately high risk of comorbidities including nonalcoholic fatty liver disease (NAFLD), cardiovascular disease, and diabetes [3–6]. NAFLD now represents the most common of all liver disorders and the most frequent cause of chronic liver disease [7]. It is a syndrome with multifactorial aetiology with which obesity is most commonly associated [8]. Obesity itself is typically a heterogeneous condition due to the regional distribution of fat tissue. There is growing evidence that the distribution of adipose tissue in the body is of importance for the development of the metabolic complications of obesity. Adipose tissue as an endocrine organ has become accepted [9, 10] with the distinctive biological properties of visceral adipose tissue presumably contributing to the increased pathogenicity of obesity.

2. Obesity and the Metabolic Syndrome

Metabolic syndrome or syndrome X (Tables 2(a), 2(b) and 3), is a constellation of closely related cardiovascular risk factors characterized by obesity, insulin resistance, hyperinsulinemia, hyperglycaemia, dyslipidemia, and hypertension [11–15]. Its pathological basis still remains elusive. Often associated with insensitivity to insulin, obesity is considered a key factor in the development of the metabolic syndrome. In obese individuals, fatty tissue becomes insensitive to the action of insulin resulting in greater breakdown of triglycerides [16]. Overabundance of circulating free fatty acids from excessive adiposity contributes to the development of insulin resistance [16]. Upon reaching insulin sensitive tissues, excessive fatty acids create insulin resistance by the added substrate availability and by modifying downstream signaling [16]. The release of adipose tissue-derived proteohormones called adipokines also comes under the influence of insulin. Under normal weight conditions, adipokines guarantee homeostasis of glucose and lipid metabolism. Their dysregulated production in the obese state is associated
with insulin resistance and appears to play an important role in the development of the metabolic syndrome [16, 17]. Resistance to Leptin, an important adipokine has been suggested as an alternative concept to explain the metabolic syndrome [16, 18]. In general, conditions like obesity in which leptin deficiency or resistance are present are associated with triglyceride accumulation in nonadipose organs like liver, muscle, and pancreas [16, 18]. The resulting lipotoxicity in these organs results in diabetes by causing insulin resistance. Leptin also seems to lower insulin secretion [16, 19]. Leptin resistance, however, could relate to the hyperinsulinemia of the metabolic syndrome [16, 20].

NAFLD represents the hepatic component of the metabolic syndrome [14, 41]. Insulin resistance is a universal phenomenon in NAFLD [14, 42, 43]. The presence of metabolic syndrome carries a high risk of necroinflammation and fibrosis among NAFLD subjects and remains strongly correlated with disease severity and progression [13, 14]. Specific adipokines may link the metabolic syndrome, type 2 diabetes and NAFLD and an imbalance in adipokine expression could play a pivotal role in disease progression to NASH and cirrhosis.

3. Adipose Tissue, Adipokines, and Inflammation

Fat is not uniformly distributed in the body (Table 4). Visceral fat depots are located in the body cavity beneath the abdominal muscles and composed of greater and lesser omentum and the mesenteric fat [23, 25, 44]. A lesser amount of visceral fat is located retroperitoneally [23, 25, 44]. In general, visceral fat accounts for up to 20% of total fat in men and 3–8% in women [44]. The abdominal subcutaneous fat is located immediately beneath the skin and on top of the abdominal musculature [25, 44]. The predominance of lower body fat is subcutaneous most of which is stored in the femoral and gluteal regions [23, 44] (Table 2).

The distribution of fat appears more important than the total fat mass in obesity [23, 45] (Table 2). A predominantly upper body fat distribution increases the risks for the metabolic complications of obesity including hepatic steatosis especially when it is associated with increased intra-abdominal fat [46–49]. Most “metabolically obese” normal weight subjects have some increase in adipose tissue mass and insulin resistance probably due to an increase in visceral fat [25]. Thus, subjects with a relatively low BMI can have gross increases in abdominal visceral fat [25, 50, 51], and others with a high BMI may have very little intra-abdominal/visceral fat [25, 52].
Adipose tissue comprises of mature adipocytes, preadipocytes, stromovascular cells, connective tissue matrix, endothelial cells, sympathetic nerve fibres, and macrophages which may all contribute to adipose tissue function [26, 49, 53]. In addition, it expresses numerous receptors that allow it to respond to afferent signals from traditional hormone systems as well as the central nervous system [49]. The cellular composition of fat can vary substantially according to anatomical location and body weight. The anatomic location of each adipose tissue depot itself affects endocrine function [25, 26, 49]. Fat mass can increase in one of two ways: individual adipocytes can increase in volume, or they can increase in number as more are derived from preadipocytes [44]. Fat cell size is an important determinant of the metabolic activity of the fat depot [45]. Visceral adipocytes are somewhat smaller than subcutaneous cells [54–56], though omental fat cell size does not differ significantly from subcutaneous adipocyte [56]. Enlarged fat cells appear to secrete increased amounts of adipokines [55, 57, 58].

The stromal vascular fraction of adipose tissue contributes to the major differences between subcutaneous and visceral fat including adipokine production. The number of stromal vascular cells per gram of adipose tissue are reported to be higher in omental compared to subcutaneous fat possibly to be due to higher number of endothelial cells in the omental fat [59]. On the other hand stromal cells from subcutaneous fat proliferate faster than those from the omental region [59]. Another component of adipose tissue, the preadipocytes, has been shown by some to show greater differentiation capacity in case of subcutaneous fat compared to visceral adipose tissue but not by others [44, 59, 60].

The increased fat mass assumes greater significance with recent recognition of the adipocyte as an endocrine organ capable of secreting a variety of bioactive peptides that exert multiple effects at both the local and systemic level [7, 49]. To date, over fifty “adipokines” have been reported to be secreted by adipose tissue that not only influence body weight homeostasis but also inflammation, coagulation, fibrinolysis, insulin resistance, diabetes, atherosclerosis, and some forms of cancer [53, 61]. These include leptin, adiponectin, resistin, acylation stimulating protein, TNF-α, TGF-β, plasminogen activator inhibitor, angiotensin II, and interleukins 6, 8, 10 [49, 53] to name a few.

The vascular anatomy and metabolic activity of fat from various depots differ in a way that may explain the association of visceral but not subcutaneous fat with obesity-related cardiovascular and metabolic problems [23, 25, 46, 58, 62] (Tables 5 and 6). Regional differences are pronounced between omental and subcutaneous fat depots [26–29, 53]. The venous drainage of visceral fat is via the portal system, directly providing free fatty acids as a substrate for hepatic lipoprotein metabolism and glucose production [23, 30, 45, 48]. Visceral omental fat has a higher rate of lipid turn over than subcutaneous fat [30, 63, 64] and omental adipocytes have higher basal and adrenaline-stimulated levels of intracellular cAMP [30, 65] being more responsive to the lipolytic effects of catecholamines [31, 64, 66], and less responsive to the antilipolytic effects of insulin [30, 64, 67, 68]. Omental adipocytes express higher levels of glucocorticoid receptors [25, 30, 69], and in very obese individuals express lower levels of lipoprotein lipase protein and mRNA than do subcutaneous adipocytes [30, 70]. Expression of IL-6, IL-8, resistin, PAI-1, MCP-1, and Visfatin is relatively greater in visceral fat compared to subcutaneous fat, whereas leptin, adiponectin, and adipin are greater in

### Table 4: Body fat distribution [27].

| Depot  | Remarks                                      |
|--------|----------------------------------------------|
| Subcutaneous | About 80% of all body fat. Can functionally be divided into abdominal and gluteofemoral |
| Visceral | Drained by the portal vein. Anatomically divided into omental, mesenteric, and retroperitoneal fat |
| Other  | Peritoneal and orbital                        |

### Table 5: Regional differences in lipolysis [27, 48].

| Hormone       | Action on lipolysis | Regional differences |
|---------------|---------------------|----------------------|
| Catecholamines| Stimulating         | VF > SCF abd > SCF glf |
| Insulin       | Inhibiting          | SCF > VF             |
| Prostaglandins| Inhibiting          | SCF > VF             |
| Adenosine     | Inhibiting          | SCF > VF             |

VF: visceral fat; SCF: subcutaneous fat; abd: abdominal; glf: gluteofemoral.

### Table 6: Differences in adipokytokines expression between visceral and subcutaneous fat in humans [28, 38, 49–52, 57, 63–67, 75].

| Adipocytokine | Differences in expression |
|---------------|--------------------------|
| Adiponectin   | VF < SCF                 |
| Adipsin       | VF < SCF                 |
| ASP           | VF < SCF                 |
| CETP          | VF < SCF                 |
| Leptin/Ob-Re  | VF < SCF                 |
| TNF-α         | VF = SCF                 |
| Angiotensinogen| VF > SCF                |
| Factor B      | VF > SCF                 |
| IL-6          | VF > SCF                 |
| IL-8          | VF > SCF                 |
| PAI-1         | VF > SCF                 |
| PPAR-γ        | VF > SCF                 |
| Resistin      | VF > SCF                 |
| VEGF          | VF > SCF                 |
| MCP-1         | VF > SCF                 |
| Visfatin      | VF > SCF                 |
| Omentin       | VF > SCF                 |

11β-HSD type 1: 11-hydroxy-steroid-dehydrogenase type 1; ASP: acylation stimulation protein; CETP: cholesterol ester transfer protein; IL-6: interleukin-6; IL-8: interleukin-8; PAI-1: plasminogen activator inhibitor-1; PPAR-γ: peroxisome proliferators-activated receptor-γ; SCF: subcutaneous fat; TNF-α: tumour necrosis factor-α; VF: visceral fat; VEGF: vascular endothelial growth factor; MCP-1: monocyte chemotactaturant protein-1.
subcutaneous adipose tissue [26, 30–36, 49, 57, 71]. There is no important regional variation of TNF-α production [25, 31, 71].

Taken as a whole, these observations suggest that visceral adipocytes may represent a specialised adipocyte population designed to release nutrients rapidly in conditions of stress.

Obesity has been characterized by a state of chronic low-grade inflammation [72, 73]. The basis of this view is an increased circulating level of several inflammatory markers in the obese including CRP, TNF-α, IL-6, IL-8, IL-18, MIF, haptoglobin, SAA, and PAI-1 [72, 74–76]. The inflammatory state may be causal in the development of insulin resistance and the metabolic syndrome [72, 76]. It remains unclear as to the extent to which adipose tissue contributes quantitatively to the elevated circulating levels of these factors and whether there is a generalised or local state of inflammation [72]. The increased production of adipokines and acute-phase proteins in obesity is considered to be primarily related to local events within the expanding fat depots [72]. With increasing evidence of the infiltration of adipose tissue by macrophages the nonadipocyte fraction may be a significant component of the inflammatory state within the fat tissue [77, 78]. Why the secretion of adipokines and other inflammation-related proteins from adipose tissue rises sharply with increasing adiposity remains obscure. It has been proposed that relative hypoxia of clusters of adipocytes within an expanding adipose tissue mass triggers the inflammatory response [72].

4. Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is a form of chronic liver disease histologically indistinguishable from alcoholic hepatitis occurring in individuals without significant alcohol consumption [79, 80]. NAFLD comprises a morphologic spectrum of liver lesions (Table 1) ranging from steatosis alone to nonalcoholic steatohepatitis (NASH), with varying risks for progression to cirrhosis [38, 79, 81]. Whereas nonalcoholic steatosis without necroinflammatory change is generally a benign condition, NASH defines the turning point in the progression of NAFLD from steatosis to advanced fibrosis and cirrhosis [8]. NASH is characterized by hepatocellular steatosis, necroinflammation, hepatocellular injury, and pericellular or perisinusoidal fibrosis [7, 82]. Isolated portal inflammation/fibrosis (IPF) signifies a subset of individuals with NAFLD who have portal fibrosis associated with hepatic steatosis in the absence of zone 3 hepatocellular injuries [83–89]. It is thought to mark the onset of disease progression [90].

5. Histological Criteria for Diagnosis

The principal histologic feature of NAFLD is the presence of macrovesicular fatty change in hepatocytes with displacement of the nucleus to the edge of the cell wall [38, 39, 91]. Additional features present variably are Mallory bodies, ballooning degeneration, predominantly lobular neutrophilic inflammation, and zone III perisinusoidal fibrosis [38, 39, 91]. In many cases, atypical features like predominantly lymphocytic inflammation and/or portal fibrosis may be seen [38, 39, 91].

6. Historical Perspectives and Prevalence

In the 1970s, fatty liver hepatitis was noticed to affect morbidly obese patients who had undergone jejunoileal bypass [92]. This was recognised as a new disease entity by Ludwig who in 1980 coined the term nonalcoholic steatohepatitis (NASH) for it [93]. Later histopathological changes consistent with the different grades of NAFLD were reported.
with certain drugs including steroids, amiodarone, and isoniazid [94–96] (Table 7). Increasingly, this entity has been expanded by its recognition as an important differential in the diagnosis of abnormal liver enzymes [97]. The prevalence of NAFLD/NASH appears to parallel the degree of obesity [7, 79, 80, 82, 98]. The prevalence of simple steatosis in obese patients is 70–100%, whereas NASH is found in 20–25% and 2–3% have cirrhosis [88, 89, 99–101]. The prevalence of IPF is approximately 29% [12, 14, 24, 27–29, 62]. Many patients with cryptogenic cirrhosis have metabolic risk factors for NAFLD and are likely to represent cases of previously unrecognised NAFLD [102, 103]. In cirrhosis, both steatosis and inflammatory changes may have disappeared making the cause difficult to establish [11, 38, 39].

7. Pathophysiology

The liver plays a central role in lipid metabolism, importing serum-free fatty acids (FFA) and manufacturing, storing, and exporting lipids and lipoproteins. However, the pathophysiology that leads to NAFLD is not well understood; in particular, the factors that lead to progressive hepatic cellular damage after triglyceride accumulation are not well elucidated. The two metabolic abnormalities most strongly associated with NAFLD are insulin resistance and an increased supply of fatty acids to the liver [104].

The “two-hit” hypothesis remains the leading theory of the pathogenesis of NAFLD [105, 106]. The “first hit,” insulin resistance, leads to steatosis as a consequence to the alterations in lipid metabolism [105, 106]. Insulin resistance results in increased FFA release from the fat stores. Hepatic FFA activity is largely uncontrolled and therefore directly proportional to plasma FFA concentrations. In the liver, FFA can either be oxidised to generate ATP or esterified to produce triglycerides which can be stored or incorporated into very low density lipoproteins for export. Defects in either of these two pathways could lead to hepatic steatosis. Hepatic lipid accumulation does not universally result in liver injury indicating that additional secondary insults are important [105]. Progression to inflammation and fibrosis appears from oxidative stress, the “second hit,” triggered by the accumulation of fatty acids producing more oxidant substances than the antioxidant processes of the liver can handle [105, 106]. Lipid peroxidation and liver damage may be influenced by a variety of factors such as cytokrome P450 2E1 induction, endotoxin, hepatic iron, Kupffer cell dysfunction, and mitochondria changes and ATP homeostasis [38, 105]. Insulin resistance can contribute to all these pathways. Portal inflammation appears to mark the occurrence of this “second hit” [90]. Alterations in the adipokines resistin, leptin, adiponectin, and TNF-α are thought also to play a role in the pathogenesis [11, 38] of NAFLD.

8. Diagnosis and Assessment of Severity

Most patients with NAFLD are asymptomatic, and typically patients are found incidentally to have abnormal biochemical liver function tests or hepatomegaly when evaluated for another condition [107, 108]. A percentage of patients present with ill-defined symptoms of right upper quadrant pain, abdominal discomfort, fatigue, or malaise [40, 97, 109, 110]. Laboratory tests are nonspecific. Most patients have a moderate elevation in transaminases, and the ALT/AST ratio is usually less than one [108]. A variable elevation of alkaline phosphatase and gammaglutamyl transpeptidase is frequent [108]. Unexplained persistent elevation of ALT is most commonly due to NAFLD once hepatitis C and other chronic liver diseases have been excluded, [91, 111]. Up to 50% have diabetes or glucose intolerance and up to 80% may reveal fasting hypertriglyceridemia [93, 109, 112, 113]. An increase of iron in the liver accompanied by an elevated saturation of transferrin and serum ferritin may be present [109]. Antinuclear antibodies have been noted in 10%–25% of NAFLD patients, the significance of which remains unclear [93, 114, 115].

Imaging studies including ultrasonography, CT scanning, and MRI are useful in demonstrating hepatic steatosis, at least when fat accumulation is moderate to severe [116–119]. However, these tests may underestimate less severe steatosis and cannot detect the differences between NASH and nonprogressive NAFLD [118–122] Liver biopsy remains the gold standard in the diagnosis and staging of NAFLD [7, 82]. It is the only diagnostic test that reliably identifies and quantifies hepatic steatosis, inflammation, necrosis, and fibrosis; and thereby estimates prognosis and disease progression [8, 120, 123–125]. It is recommended during bariatric surgery to assess the extent of liver damage, the behaviour of liver architecture after weight loss, and the relevance of NASH in the evolution to cirrhosis [126, 127]. In addition to confirming the clinical diagnosis, liver biopsy is valuable for excluding other liver disease and for monitoring treatment efficacy [82, 128, 129]. Disadvantages to biopsy include observer variability, sampling variation, and morbidity and mortality [130].

To date, few investigations have specifically addressed sampling error and variability in NASH. Sampling variability has the potential to significantly alter disease grade and stage. The histological findings of NAFLD are usually presumed to be homogenously distributed throughout the liver. Consequently, in clinical practice, a single random core biopsy is usually considered representative of overall hepatic involvement. However, there are no data to support these assumptions in NASH [131].

Broadly, two different types of liver biopsy techniques are in use: core (needle) biopsy and wedge biopsy. Needle biopsy can be obtained percutaneously either blindly or under radiological or ultrasound guidance and by transjugular catheter [130, 132, 133]. Both types of biopsies can be taken during laparoscopic or open surgery [130, 132–134]. Core biopsy has declined considerably at laparotomy or laparoscopy and is now used mainly when focal lesions are discovered during routine surgery [133]. Wedge biopsy of the liver yields more accurate diagnosis of liver diseases than does needle biopsy, but is more invasive and haemostasis more problematic [135].

Types of biopsy needles include: the Tru-Cut, which is a cutting needle, and the Menghini needle, which uses a suction technique [132, 133, 136]. The cutting needle usually
produces a larger sample, but is associated with a higher risk of complications. A suction needle tends to produce more fragmented samples [132, 137]. The size of the specimen varies depending on the size of needle; a biopsy obtained with 14-gauge (G) to 21G needle is usually defined as large, whereas needles less than 21G result in thin or fine biopsy samples with a core less than 1 mm in diameter. The size of the biopsy specimen that varies between 1 and 3 cm in length and between 1.2 and 2 mm in diameter represents 1/50,000 to 1/100,000th of the total mass of the liver [130, 132, 133]. The traditional assumption that a sample 1.5 cm long or containing four to six portal tracts, or both, is adequate is no longer true for the grading and staging of chronic liver disease. Studies show that smaller samples significantly underestimate the disease severity and samples at least 2 cm long can ensure greater diagnostic accuracy [133, 138].

In NAFLD, the distinction between steatosis and steatohepatitis and the assessment of the severity rely entirely on liver histology. Small unrepresentative samples in the context of uneven distribution of lesions can result in substantial misdiagnosis and staging inaccuracies. In addition, important pathology can be overlooked if only a single biopsy specimen is taken. It is suggested that three consecutive specimens may improve the diagnostic yield of liver biopsy [139]. While sampling error has been studied fairly extensively in cases of needle biopsy, this is not true in cases of wedge liver biopsy especially in the context of NASH.

9. Progression of Liver Disease

Knowledge about the natural history of NAFLD is still evolving. There are several distinct histologic states that indicate progression of the lesion: fatty liver alone, steatohepatitis, steatohepatitis with fibrosis, and eventually cirrhosis [91, 97]. The precise risk of mortality in patients with NAFLD is not known. Preliminary studies suggest a more benign course for simple steatosis and the mortality remains low, although some have shown occasional progression to cirrhosis [38, 40, 140]. Cross-sectional series have shown that 30–40% of patients with NASH have advanced liver fibrosis at the time of presentation [91, 97, 141], whereas 10–15% may have established cirrhosis [7, 109, 141]. The risk for developing increased fibrosis in NASH over 5 years is 25% and for developing cirrhosis is 15% [38, 97, 142]. The 5- and 10-year survival in NASH has been estimated at 67% and 59% respectively, although death may arise from comorbid conditions [38, 143]. NAFLD is a leading cause of “cryptogenic cirrhosis” in which aetiologically specific clinical, laboratory, or pathological features can no longer be identified [102, 144, 145]. NAFLD-associated cirrhosis can develop into subacute liver failure, progress to hepatocellular carcinoma, and recur post-transplantation [125, 144, 146]. Thus, it appears that NAFLD is associated with the entire spectrum of chronic liver disease: progressive fibrosis, cirrhosis, end-stage liver disease, and hepatocellular carcinoma. A number of risk factors have been identified as predictors for progressive fibrosis and cirrhosis in NAFLD including; BMI > 30, type II diabetes, age > 45 years, and an ALT : AST ratio > 1 [7].

Histologic improvement may also occur with weight loss, especially in those with only minimal fibrosis [147]. This is particularly true when weight loss is achieved slowly [147, 148]. Rapid weight loss has been noted to accelerate disease progression [101, 149, 150]. Liver failure becomes manifest in many cases during a period of rapid weight loss regardless of its mechanism [101, 149, 151].

It is clear that patients with NAFLD and even more so with NASH have a serious liver disease with a fibrogenic potential that can result in liver-related morbidity and mortality.

10. Visceral Fat and NAFLD

Despite the high prevalence of NAFLD and its potential for serious sequelae, the underlying aetiological factors that determine disease progression from simple steatosis to NASH and cirrhosis remain poorly understood. Disordered adipokine production is likely to play a role in the pathogenesis of NAFLD [106, 152]. Adipokines are implicated in the pathogenesis of NAFLD/NASH through their metabolic and pro-/anti-inflammatory activity [153]. The literature reveals quantitative and qualitative differences in the repertoire of mediators that are released from peripheral and visceral fat depots [154, 155] (Table 6). The net adipokine profile generated by visceral fat appears more noxious than that of subcutaneous fat [60]. Hence, visceral adiposity accompanies the metabolic syndrome [60, 154]. Increasing visceral obesity is thought to result in increased production of proinflammatory cytokines and adipokines [tumour necrosis factor alpha, interleukin 6, and C reactive protein] [26, 156–158] and decreased production of protective adipokines [adiponectin] [28, 153, 156]. This abnormal balance might ultimately lead to the clinical and histopathological occurrence of NASH.

The exact role of adipokines in the pathogenesis of NAFLD, however, remains investigative. Literature reveals variable results about alteration in leptin [159–161], adiponectin, and TNF-α [153, 162] while the role of resistin in NAFLD in humans still awaits to be examined [162–164] though increased resistin levels have been correlated with NAFLD severity and NASH development [165, 166]. Investigators have shown a direct dose-dependent link between increasing amounts of visceral fat and end-organ tissue inflammation and fibrosis in patients with NAFLD demonstrating visceral fat to be directly associated with liver inflammation and scarring in the metabolic syndrome [166, 167]. Importantly, this effect was independent of levels of hepatic steatosis, patient age, and insulin resistance [166, 167]. Ethnic differences in visceral fat are being investigated as potential links to understanding differences in NAFLD. Compared to Caucasians, lower levels of hepatic triglycerides have been found in African Americans despite similar total body adiposity and insulin resistance [166, 168], whilst Asians have increased visceral fat depots in relation to their body mass index (BMI) risking NAFLD despite low BMI [166, 169].
11. Conclusion

The growing epidemic of obesity across the globe constitutes a major challenge to health services. Nonalcoholic fatty liver disease (NAFLD) has become the most common of all liver disorders with prevalence paralleling the degree of obesity. A clear understanding of the mechanisms underlying disease progression is urgently required to develop prevention and treatment strategies. Adipokines secreted by adipose tissue have recently been implicated in initiating and perpetuating the chronic inflammatory state observed in obesity and NAFLD. Studies should be undertaken to examine the exact role of adipokines derived from intra-abdominal fat as these appear to be the main drivers for the development of progressive liver injury in patients with severe obesity.

References

[1] J. C. Seidell, "Epidemiology of obesity," Seminars in Vascular Medicine, vol. 5, no. 1, pp. 3–14, 2005.
[2] The World Health Organization, "Preventing and managing the global epidemic," WHO Technical Report Series 894, Geneva, Switzerland, 2000.
[3] J. G. Kral, F. Schaffner, R. N. Pierson, and J. Wang, "Body fat topography as an independent predictor of fatty liver," Metabolism, vol. 42, no. 5, pp. 548–551, 1993.
[4] G. Ramsey-Stuart, "Hepatic steatosis and morbid obesity," Obesity Surgery, vol. 3, no. 2, pp. 157–159, 1993.
[5] W. van Steenbergen and S. Lanckmans, "Liver disturbances in obesity and diabetes mellitus," International Journal of Obesity, vol. 19, supplement 1, pp. S27–S36, 1995.
[6] A. M. Wolf, B. Busch, H. W. Kuhlmann, and U. Beisiegel, "Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters," Obesity Surgery, vol. 15, no. 2, pp. 228–237, 2005.
[7] W. I. Youssef and A. J. McCullough, "Steatohepatitis in obese individuals," Best Practice and Research in Clinical Gastroenterology, vol. 16, no. 5, pp. 733–747, 2002.
[8] D. Festi, A. Colecchia, T. Sacco, M. Bondi, E. Roda, and G. Marchesini, "Hepatic steatosis in obese patients: clinical aspects and prognostic significance," Obesity Reviews, vol. 5, no. 1, pp. 27–42, 2004.
[9] C. J. Lyon, R. E. Law, and W. A. Hsueh, "Minireview: adiposity, inflammation, and atherogenesis," Endocrinology, vol. 144, no. 6, pp. 2195–2200, 2003.
[10] S. Mora and J. E. Pessin, "An adipocentric view of signaling and intracellular trafficking," Diabetes/Metabolism Research and Reviews, vol. 18, no. 5, pp. 345–356, 2002.
[11] E. M. Brunt, "Nonalcoholic steatohepatitis," Seminars in Liver Disease, vol. 24, no. 1, pp. 3–20, 2004.
[12] A. Lonardo, "Fatty liver and nonalcoholic steatohepatitis: where do we stand and where are we going?" Digestive Diseases, vol. 17, no. 2, pp. 80–89, 1999.
[13] G. Marchesini, E. Bugiansi, G. Forlani et al., "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome," Hepatology, vol. 37, no. 4, pp. 917–923, 2003.
[14] P. Marceau, S. Biron, F. S. Hould et al., "Liver pathology and the metabolic syndrome X in severe obesity," Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 5, pp. 1513–1517, 1999.
[15] K. G. M. M. Alberti, P. Zimmet, and J. Shaw, "The metabolic syndrome—a new worldwide definition," Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005.
[16] R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, "The metabolic syndrome," Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005.
[17] Y. Matsuzawa, T. Funahashi, and T. Nakamura, "Molecular mechanism of metabolic syndrome X: contribution of adipocytokines-adipocyte-derived bioactive substances," Annals of the New York Academy of Sciences, vol. 892, pp. 146–154, 1999.
[18] R. H. Unger, "Lipid overload and overflow: metabolic trauma and the metabolic syndrome," Trends in Endocrinology and Metabolism, vol. 14, no. 9, pp. 398–403, 2003.
[19] J. A. Cases, I. Gabriely, X. H. Ma et al., "Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo," Diabetes, vol. 50, no. 2, pp. 348–352, 2001.
[20] J. Seufert, "Leptin effects on pancreatic b-cell gene expression and function," Diabetes, vol. 53, no. 1, pp. 152–158, 2004.
[21] P. Z. Zimmet, K. G. M. M. Alberti, and J. Shaw, "A new IDF worldwide definition of the metabolic syndrome: the rationale and the results," Diabetes Voice, vol. 50, no. 3, pp. 31–33, 2005.
[22] E. S. Ford, W. H. Giles, and W. H. Dietz, "Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey," Journal of the American Medical Association, vol. 287, no. 3, pp. 356–359, 2002.
[23] P. Arner, "Regional adiposity in man," Journal of Endocrinology, vol. 155, no. 11, pp. 191–192, 1997.
[24] P. Arner, "Differences in lipolysis between human subcutaneous and omental adipose tissues," Annals of Medicine, vol. 27, no. 4, pp. 435–438, 1995.
[25] B. L. Wajchenberg, "Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome," Endocrine Reviews, vol. 21, no. 6, pp. 697–738, 2000.
[26] J. N. Fain, A. K. Madan, M. L. Hiler, P. Cheema, and S. W. Bahouth, "Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans," Endocrinology, vol. 145, no. 5, pp. 2273–2282, 2004.
[27] E. Dusserre, P. Moulin, and H. Vidal, "Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues," Biochimica et Biophysica Acta, vol. 1500, no. 1, pp. 88–96, 2000.
[28] A. S. Lihn, J. M. Bruun, G. He, S. B. Pedersen, P. F. Jensen, and B. Richelsen, "Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects," Molecular and Cellular Endocrinology, vol. 219, no. 1–2, pp. 9–15, 2004.
[29] A. Schaffler, J. Scholmerich, and C. Buchler, "Mechanisms of disease: adipocytokines and visceral adipose tissue—emerging role in nonalcoholic fatty liver disease," Nature Clinical Practice Gastroenterology and Hepatology, vol. 2, no. 6, pp. 273–280, 2005.
[30] C. T. Montague, J. B. Prins, L. Sanders et al., "Depot-related gene expression in human subcutaneous and omental adipocytes," Diabetes, vol. 47, no. 9, pp. 1384–1391, 1998.
[31] V. van Harmelen, A. Dicker, M. Rydén et al., "Increased lipolysis and decreased leptin production by human omental fat: possible role of the lipolytic enzyme uridine diphosphate glucose: lipase A in the regulation of adipocytokine secretion," Journal of Clinical and Investigative Medicine, vol. 33, no. 2, pp. 1059–1069, 1999.
[32] K. G. M. M. Alberti, P. Zimmet, and J. Shaw, "The metabolic syndrome—a new worldwide definition," Lancet, vol. 365, no. 9491, pp. 1059–1062, 2005.
[66] H. Wahrenberg, F. Lonnqvist, and P. Arner, “Mechanisms underlying regional differences in lipolysis in human adipose tissue,” *Journal of Clinical Investigation*, vol. 84, no. 2, pp. 458–467, 1989.

[67] J. Bolinder, L. Kager, J. Ostman, and P. Arner, “Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis,” *Diabetes*, vol. 32, no. 2, pp. 117–123, 1983.

[68] B. Richelsen, S. B. Pedersen, T. Moller-Pedersen, and J. F. Bak, “Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2,” *Metabolism*, vol. 40, no. 9, pp. 990–996, 1991.

[69] M. Rebuffe-Scrive, M. Bronnegard, A. Nilsson, J. Eldh, J. A. Gustafsson, and P. Bjornstorp, “Steroid hormone receptors in human adipose tissues,” *Journal of Clinical Endocrinology and Metabolism*, vol. 71, no. 5, pp. 1215–1219, 1990.

[70] S. K. Fried, C. D. Russell, N. L. Grauso, and R. E. Brolin, “Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men,” *Journal of Clinical Investigation*, vol. 92, no. 5, pp. 2191–2198, 1993.

[71] P. Arner, “Regional differences in protein production by human adipose tissue,” *Biochemical Society Transactions*, vol. 29, no. 2, pp. 72–75, 2001.

[72] P. Traylor and I. S. Wood, “Adipokines: inflammation and the pleiotropic role of white adipose tissue,” *British Journal of Nutrition*, vol. 92, no. 3, pp. 347–355, 2004.

[73] J. S. Yudkin, C. D. A. Stehouwer, J. J. Emeis, and S. W. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. J. S. Yudkin, “Adipose tissue, insulin action and vascular disease,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 19, no. 4, pp. 972–978, 1999.

[74] M. W. Rajala and P. E. Scherer, “Minireview: the adipocyte—a potential role for cytokines originating from adipose tissue with obesity, insulin resistance, and endothelial dysfunction: the pleiotropic role of white adipose tissue,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 29, no. 2, pp. 72–75, 2001.

[75] P. Traylor and I. S. Wood, “Signalling role of adipose tissue: adipokines and inflammation in obesity,” *Biochemical Society Transactions*, vol. 33, no. 5, pp. 1078–1081, 2005.

[76] J. S. Yudkin, “Adipose tissue, insulin action and vascular disease: inflammatory signals,” *International Journal of Obesity*, vol. 27, no. 3, pp. S25–S28, 2003.

[77] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” *Journal of Clinical Investigation*, vol. 112, no. 12, pp. 1796–1808, 2003.

[78] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” *Journal of Clinical Investigation*, vol. 112, no. 12, pp. 1821–1830, 2003.

[79] P. Haynes, S. Liangpunsakul, and N. Chalasani, “Nonalcoholic fatty liver disease in individuals with severe obesity,” *Clinics in Liver Disease*, vol. 8, no. 3, pp. 535–547, 2004.

[80] A. E. Reid, “Nonalcoholic steatohepatitis,” *Gastroenterology*, vol. 121, no. 3, pp. 710–723, 2001.

[81] T. Gramlich, D. E. Kleiner, A. J. McCullough, C. A. Matteoni, N. Boparai, and Z. M. Younossi, “Pathologic features associated with fibrosis in nonalcoholic fatty liver disease,” *Human Pathology*, vol. 35, no. 2, pp. 196–199, 2004.

[82] M. Charlton, “Nonalcoholic fatty liver disease: a review of current understanding and future impact,” *Clinical Gastroenterology and Hepatology*, vol. 2, no. 12, pp. 1048–1058, 2004.
Effects of drastic weight loss after gastroplasty,” *International Journal of Obesity*, vol. 22, pp. 222–226, 1998.

[102] S. H. Caldwell, D. H. Oelsner, J. C. Iezzoni, E. E. Hesonheide, E. H. Battle, and C. J. Driscoll, “Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease,” *Hepatology*, vol. 29, no. 3, pp. 664–669, 1999.

[103] A. Poonawala, S. P. Nair, and P. J. Thuluvath, “Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study,” *Hepatology*, vol. 32, no. 4, pp. 689–692, 2000.

[104] F. H. Luyckx, P. J. Lefebvre, and A. J. Scheen, “Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss,” *Diabetes and Metabolism*, vol. 26, no. 2, pp. 98–106, 2000.

[105] C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two hits?” *Gastroenterology*, vol. 114, no. 4, pp. 842–845, 1998.

[106] C. P. Day, “Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?” *Gut*, vol. 50, no. 5, pp. 585–588, 2002.

[107] G. C. Farrell and C. Z. Larter, “Non-alcoholic fatty liver disease: from steatosis to cirrhosis,” *Hepatology*, vol. 37, no. 6, pp. 1286–1292, 2003.

[108] P. Mofrad, M. J. Contos, M. Haque et al., “Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values,” *Hepatology*, vol. 37, no. 6, pp. 1370–1371, 2004.

[109] E. E. Powell, W. G. Cooksley, R. Hanson, J. Searle, J. W. Halliday, and L. W. Powell, “The natural history of non-alcoholic steatohepatitis: a followup study of forty-two patients for up to 21 years,” *Hepatology*, vol. 11, pp. 74–80, 1990.

[110] S. G. Sheth, F. D. Gordon, and S. Chopra, “Nonalcoholic steatohepatitis,” *Annals of Internal Medicine*, vol. 126, no. 2, pp. 137–145, 1997.

[111] A. Sonsuz, M. Basaranoglu, and G. Ozbay, “Relationship between aminotransferase levels and histopathological findings in patients with non-alcoholic steatohepatitis,” *The American Journal of Gastroenterology*, vol. 95, no. 4, pp. 1056–1062, 1998.

[112] S. J. Cotler, K. Kanji, A. Keshavarzian, D. M. Jensen, and S. Jakate, “Prevalence and significance of autoimmune hepatitis in patients with non-alcoholic steatohepatitis,” *Journal of Clinical Gastroenterology*, vol. 38, no. 9, pp. 801–804, 2004.

[113] K. Tajiri, H. Takanawa, K. Yamaoka, M. Yamane, F. Marumo, and C. Sato, “Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis,” *Journal of Clinical Gastroenterology*, vol. 25, no. 3, pp. 538–540, 1997.

[114] K. J. Mortele and P. R. Ros, “Imaging of diffuse liver disease,” *Seminars in Liver Disease*, vol. 21, no. 2, pp. 195–212, 2001.

[115] C. C. Mottin, M. Moretto, A. V. Padoin et al., “The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients,” *Obesity Surgery*, vol. 14, no. 5, pp. 635–637, 2004.

[116] H. Ataseven, M. H. Yildirim, M. Yalniz, H. Bahccecioglu, S. Celebi, and I. H. Ozceran, “The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis,” *Gastroenterology in Belgium*, vol. 68, pp. 221–225, 2003.
Royal College of Physicians of London, "Gut," vol. 36, no. 3, pp. 437–441, 1995.

[137] F. Piccinino, E. Sagnelli, and G. Pasquale, “Complications following percutaneous liver biopsy,” Journal of Hepatology, vol. 2, no. 2, pp. 165–173, 1986.

[138] G. Collorredo, M. Guido, A. Sonzogni, and G. Leandro, “Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease,” Journal of Hepatology, vol. 39, no. 2, pp. 239–244, 2003.

[139] B. Maharaj, R. J. Maharaj, and W. P. Leary, “Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver,” Lancet, vol. 1, no. 8480, pp. 523–525, 1986.

[140] S. A. Harrison, S. Torgerson, and P. H. Hayashi, “The natural history of nonalcoholic fatty liver disease: a clinical histopathological study,” American Journal of Gastroenterology, vol. 98, no. 9, pp. 2042–2047, 2003.

[141] E. Fassio, E. Alvarez, N. Domínguez, G. Landeira, and C. Longo, “Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies,” Hepatology, vol. 40, no. 4, pp. 820–826, 2004.

[142] V. Ratziau, P. Giralt, F. Charlotte, E. Bruckert, V. Thibault, and I. Theodorou, “Liver fibrosis in over weight patients,” Gastroenterology, vol. 118, pp. 1117–1123, 2000.

[143] A. Propst, T. Propst, G. Zangerl, D. Ofner, G. Judmaier, and W. Vogel, “Prognosis and life expectancy in chronic liver disease,” Digestive Diseases and Sciences, vol. 40, no. 8, pp. 1805–1815, 1995.

[144] E. Bugianesi, N. Leone, E. Vanni et al., “Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma,” Gastroenterology, vol. 123, no. 1, pp. 134–140, 2002.

[145] J. M. Clark and A. M. Diehl, “Nonalcoholic fatty liver disease. An underrecognized cause of crypto-genic cirrhosis,” Journal of the American Medical Association, vol. 289, no. 22, pp. 300–304, 2003.

[146] A. J. McCullough, “The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease,” Clinics in Liver Disease, vol. 8, no. 3, pp. 521–533, 2004.

[147] J. B. Dixon, P. S. Bhathal, N. R. Hughes, and P. E. O’Brien, “Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss,” Hepatology, vol. 39, no. 6, pp. 1647–1654, 2004.

[148] S. Eriksson, K. F. Eriksson, and L. Bondesson, “Nonalcoholic steatohepatitis in obesity: a reversible condition,” Acta Medica Scandinavica, vol. 220, no. 1, pp. 83–88, 1986.

[149] T. Andersen, C. Gluud, M. B. Franzmann, and P. Christofersen, “Hepatic effects of dietary weight loss in morbidly obese subjects,” Journal of Hepatology, vol. 12, no. 2, pp. 224–229, 1991.

[150] F. H. Luyckx, A. J. Scheen, C. Desaive, W. Dewe, J. E. Gielen, and P. J. Lefebvre, “Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity,” Diabetes and Metabolism, vol. 24, no. 4, pp. 355–361, 1998.

[151] E. J. Drenick, F. Simmons, and J. F. Murphy, “Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass,” New England Journal of Medicine, vol. 282, no. 15, pp. 829–834, 1970.

[152] H. Tilg and A. M. Diehl, “Cytokines in alcoholic and non-alcoholic steatohepatitis,” New England Journal of Medicine, vol. 343, no. 20, pp. 1467–1476, 2000.

[153] J. M. Hui, A. Hodge, G. C. Farrell, J. G. Kench, A. Kriekos, and I. George, “Beyond insulin resistance in NASH: TNF-α or adiponectin?” Hepatology, vol. 40, no. 1, pp. 46–54, 2004.

[154] S. Choi and A. M. Diehl, “Role of inflammation in nonalcoholic steatohepatitis,” Current Opinion in Gastroenterology, vol. 21, no. 6, pp. 702–707, 2005.

[155] G. Atzmon, X. M. Yang, R. Muzumdar, X. H. Ma, I. Gabriely, and N. Barzilai, “Differential gene expression between visceral and subcutaneous fat depots,” Hormone and Metabolic Research, vol. 34, no. 11-12, pp. 622–628, 2002.

[156] C. J. Lyon, R. E. Law, and W. A. Hsueh, “Minireview: adiposity, inflammation, and atherogenesis,” Endocrinology, vol. 144, no. 6, pp. 2195–2200, 2003.

[157] P. Ziccardi, F. Nappo, G. Giugliano et al., “Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year,” Circulation, vol. 105, no. 7, pp. 804–809, 2002.

[158] M. Lehrke, M. P. Reilly, S. C. Millington, N. Iqbal, D. J. Rader, and M. A. Lazar, “An inflammatory cascade leading to hyperresistinemia in humans,” PLoS Medicine, vol. 1, pp. 161–168, 2004.

[159] S. Chitturi, G. Farrell, L. Frost et al., “Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?” Hepatology, vol. 36, no. 2, pp. 403–409, 2002.

[160] N. Chalasani, D. W. Crabb, O. W. Cummings et al., “Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?” American Journal of Gastroenterology, vol. 98, no. 12, pp. 2771–2776, 2003.

[161] P. Angulo, L. M. Alba, L. M. Petrovic, L. A. Adams, K. D. Lindor, and M. D. Jensen, “Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease,” Journal of Hepatology, vol. 41, no. 6, pp. 943–949, 2004.

[162] G. Musso, R. Gambino, M. Durazzo et al., “Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease,” Hepatology, vol. 42, no. 5, pp. 1175–1183, 2005.

[163] M. J. Czaja, “Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine,” Hepatology, vol. 40, no. 1, pp. 19–22, 2004.

[164] J. Janke, S. Angeli, K. Gorzelniak, F. C. Luft, and A. M. George, “Beyond insulin resistance in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease,” Hepatology, vol. 161–168, 2004.

[165] C. Pagano, G. Soardo, C. Pilone et al., “Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, pp. 1081–1086, 2006.

[166] D. G. Tiniakos, M. B. Vos, and E. M. Brunet, “Nonalcoholic fatty liver disease,” Annual Review of Pathology, vol. 5, pp. 145–171, 2010.

[167] D. Van Der Poorten, K. L. Milner, J. Hui et al., “Visceral fat: a key mediator of steatohepatitis in metabolic liver disease,” Hepatology, vol. 48, no. 2, pp. 449–457, 2008.

[168] R. Guerrero, G. L. Vega, S. M. Grundy, and J. D. Browning, “Ethnic differences in hepatic steatosis: an insulin resistance paradox?” Hepatology, vol. 49, no. 3, pp. 791–801, 2009.

[169] S. R. Weston, W. Leyden, R. Murphy, N. M. Bass, and B. P. Bell, “Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease,” Hepatology, vol. 41, pp. 372–379, 2005.